Sujatha Baddam

Dr. Sujatha Baddam

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
NKNavkirat Kahlon
Navkirat Kahlon
SBSujatha Baddam
Sujatha Baddam
NBNahush Bansal
Nahush Bansal
ZQZaheer Qureshi
Zaheer Qureshi
JMJhansi Maradana
Jhansi Maradana
Breast cancer receptor status plays a critical role in treatment selection, yet receptor evolution throughout disease progression remains a significant challenge. This case describes a 58-year-old female initially diagnosed with estrogen receptor (ER)-positive (95%), progesterone receptor (PR)-negative (<5%), human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry [IHC] 0, fluorescence in situ hybridization-negative) invasive ductal carcinoma. Over 6 years, her tumor transitioned to triple-negative breast cancer at recurrence, then reacquired ER expression (80%) in metastatic mediastinal lymph nodes. HER2 status evolved from IHC 0 → HER2-low (IHC 1+ → IHC 2+), directly influencing therapy selection. These receptor changes led to major systemic treatment modifications, including endocrine therapy, immunotherapy, CDK4/6 inhibitors, and antibody–drug conjugates. Given the extended response duration and improved tolerability of targeted therapies, accurate receptor assessment is essential to ensure that patients receive the most effective treatment. Literature reports receptor discordance rates of ER loss (19%), PR loss (34%), and HER2 fluctuations (15%), reinforcing the necessity of biopsy-driven treatment adaptation. While serial biopsies remain invasive, they provide essential molecular insights that optimize systemic therapy choices, allowing patients to remain on the most appropriate, well-tolerated regimen for as long as possible. This case highlights the clinical significance of receptor evolution and advocates for biopsy-guided precision oncology in metastatic breast cancer management. Ensuring accurate receptor reassessment through periodic molecular profiling can maximize therapeutic efficacy, improving response rates, treatment tolerability, and overall patient outcomes.

23 April 2025 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
SBSujatha Baddam
Sujatha Baddam
SMSanjay Muttineni
Sanjay Muttineni
Lactic acidosis is a serious condition often associated with tissue hypoxia or sepsis, but it can also be caused by beta-adrenergic agonists such as albuterol. This report describes a case of albuterol-induced lactic acidosis in a male patient in his 70s with chronic obstructive pulmonary disease exacerbation. The patient presented with progressively worsening dyspnoea and increased albuterol use. During the initial evaluation, an elevated lactate level was observed, which further increased after albuterol treatment in the emergency room. A thorough sepsis workup was performed, yielding negative results, which ultimately led to the diagnosis of albuterol-induced lactic acidosis. After reducing the frequency of albuterol treatments, the patient’s lactate levels normalised. This case underscores the importance of considering medication-induced causes of lactic acidosis, particularly in patients with respiratory conditions who are frequently administered beta-adrenergic agonists. Recognising this under-reported phenomenon can help clinicians avoid unnecessary sepsis workups and ensure more accurate treatment plans.

19 April 2025 in American Journal of Case Reports
Verified
Journal Article
Open access
MTMrudula Thiriveedi
Mrudula Thiriveedi
FDFrancis G. Sto. Domingo
Francis G. Sto. Domingo
SLSawyer Longley
Sawyer Longley
SPSiddharth Patel
Siddharth Patel
SBSujatha Baddam
Sujatha Baddam
ACAnil Chimakurthy
Anil Chimakurthy
BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to the emergence of various neurological complications, including Guillain-Barre syndrome (GBS). GBS is an acute, immune-mediated disorder characterized by progressive weakness, sensory deficits, and autonomic dysfunction. Anti-ganglioside antibodies are often seen in GBS; however, they are rarely reported in the setting of COVID-19-related GBS. We present a case of post-COVID-19 GBS with positive GM1 and GD1b antibodies. CASE REPORT An 86-year-old man presented with progressive quadriparesis, sensory deficits, and hyporeflexia 4 weeks after COVID-19 infection. Brain and spine imaging were unremarkable. Cerebrospinal fluid (CSF) analysis revealed albuminocytological dissociation, consistent with acute inflammatory demyelinating polyneuropathy (AIDP). Despite 2 courses of intravenous immunoglobulin (IVIG), the patient showed minimal improvement in muscle strength. Nerve conduction studies (NCS) revealed severe sensorimotor polyneuropathy, with axonal and demyelinating features. Serum testing showed elevated GM1 and GD1b anti-ganglioside antibody titers. CONCLUSIONS Although numerous cases of COVID-19-related GBS have been reported, anti-ganglioside antibody positivity, particularly GM1 and GD1b, is uncommon. The underlying mechanism is presumed to be autoimmune, likely triggered by molecular mimicry. Our case contributes to the evolving understanding of GBS immunology in the context of COVID-19. Although this case report may not alter current GBS management, the co-occurrence of GM1 and GD1b antibodies in post-COVID-19 GBS underscores the need for continued vigilance, immunological profiling, and research into potential prognostic and therapeutic implications.

29 May 2025 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
SBSujatha Baddam
Sujatha Baddam
SPSiddharth Patel
Siddharth Patel
NKNavkirat Kahlon
Navkirat Kahlon
MTMrudula Thiriveedi
Mrudula Thiriveedi
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare but emerging central nervous system demyelinating disorder that can mimic other neurological conditions. The use of TNF-alpha inhibitors in patients with autoimmune diseases has been linked to central nervous system demyelinating events, but the relationship remains poorly understood. Case description: We present a 64-year-old male with a history of ankylosing spondylitis previously treated with a TNF-alpha inhibitor who developed progressive dizziness, ataxia, visual disturbances and cognitive changes. Despite extensive workup, including imaging and cerebrospinal fluid analysis, initial evaluations were inconclusive. MRI was non-diagnostic, and cerebrospinal fluid lacked oligoclonal bands. Ultimately, a serum MOG antibody titre of 1:1,000 confirmed the diagnosis of MOGAD. The patient improved with intravenous corticosteroids and was discharged on a tapering dose of oral prednisone. This case highlights an MRI-negative presentation of MOGAD with strong serologic findings. Conclusion: This case emphasises the diagnostic challenge of MOGAD in patients with autoimmune backgrounds and neurologic symptoms without clear imaging findings. Clinicians should consider MOGAD in the differential diagnosis when evaluating such patients, particularly those with prior TNF-alpha inhibitor exposure. Early recognition and treatment with immunotherapy can lead to significant clinical improvement.

19 February 2025 in American Journal of Case Reports
Verified
Journal Article
Open access
SBSujatha Baddam
Sujatha Baddam
MTMrudula Thiriveedi
Mrudula Thiriveedi
SPSiddharth Patel
Siddharth Patel
BACKGROUND Cytomegalovirus (CMV) infection is typically asymptomatic in immunocompetent individuals but can cause severe complications, such as immune thrombocytopenic purpura (ITP). This case report describes an uncommon instance of CMV-induced ITP in a 36-year-old immunocompetent man who was refractory to steroids and intravenous immunoglobulin (IVIG) and responded to antiviral therapy. CASE REPORT A previously healthy 36-year-old White man presented with flu-like symptoms, including subjective fevers, anorexia, nausea, cough, and a 6.8-kg weight loss over 2 weeks. Initial laboratory test results revealed severe thrombocytopenia (platelet count 4×10⁹/L) alongside elevated lymphocyte counts and mild splenomegaly. Additional serology confirmed a positive CMV IgM antibody. The patient was identified as having ITP and was treated with high-dose methylprednisolone and platelet transfusion, leading to initial platelet recovery. However, he returned within a week with severe epistaxis and a critical drop in platelet count to 0×10⁹/L. Subsequent testing confirmed CMV infection, with a viral load of 8790 copies/mL viral load. After unsuccessful IVIG treatment, antiviral therapy with valganciclovir was initiated, leading to a sustained increase in platelet count and eventual symptom resolution. CONCLUSIONS CMV-induced ITP, although rare in immunocompetent individuals, should be considered in cases of refractory thrombocytopenia unresponsive to standard therapies. Prompt diagnosis and the initiation of targeted antiviral therapy are crucial for effective recovery, as they address the underlying viral etiology and can significantly improve patient outcomes. This case underscores the importance of including CMV in the differential diagnosis for persistent thrombocytopenia to ensure timely and appropriate treatment.

26 February 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SPSiddharth Mbbs Patel
Siddharth Mbbs Patel
ARAmogh Reddy
Amogh Reddy
MAMc Anto Antony
Mc Anto Antony
MTMrudula Thiriveedi
Mrudula Thiriveedi
PPPrutha Mbbs Pathak
Prutha Mbbs Pathak
HRHinal Do Rathi
Hinal Do Rathi
Diabetes mellitus is a chronic medical condition which affects millions of adults worldwide. It can result in various complications and is associated with a higher rate of hospitalizations. Blood glucose management in hospitalized patients is a critical aspect of care, which is important for preventing complications, improving patient outcomes, and reducing the length of hospital stay. Blood glucose control is difficult to achieve secondary to multiple factors involved in its regulation (e.g. type of medical illness, corticosteroid use, and enteral feeding) as well as varying evidence to determine different aspects of it. Our goal is to summarize the existing evidence from observational studies, clinical trials, and various society guidelines on blood glucose management in the hospitalized setting. Export